Compare RFL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFL | KZIA |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.1M | 125.6M |
| IPO Year | 2017 | 2002 |
| Metric | RFL | KZIA |
|---|---|---|
| Price | $1.05 | $6.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $28.76 |
| AVG Volume (30 Days) | 53.3K | ★ 173.7K |
| Earning Date | 12-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $0.99 | $4.86 |
| 52 Week High | $3.96 | $17.40 |
| Indicator | RFL | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 32.56 |
| Support Level | $0.99 | $4.86 |
| Resistance Level | $1.38 | $14.85 |
| Average True Range (ATR) | 0.11 | 0.66 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 12.88 | 14.94 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.